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a b s t r a c t
To estimate the cost-effectiveness of a potential Helicobacter pylori (HP) vaccine for the Dutch situation,
we developed a Markov model. Several HP prevalence scenarios were assessed. Additionally, we assessed
the impact of the discount rate for health on the outcomes, as this inﬂuence can be profound for vac-8 November 2008
ccepted 22 November 2008
vailable online 11 December 2008
eywords:
elicobacter pylori
cines. When applying the current discount rate of 1.5% for health, the expected cost-effectiveness of HP
vaccination is estimated below the informal Dutch threshold of D 20,000/LYG when the HP prevalence is
assumed ≥20% in the Dutch population. In conclusion, we showed that HP vaccination could possibly be a
cost-effective intervention. However, this depends to a large extend on the prevalence of HP in the popu-
lation. Furthermore, we showed the large impact of the discount rate for health on the cost-effectiveness
am, ilost-effectiveness
iscount rate
of a HP vaccination progr
. Introduction
The prevalence of Helicobacter pylori (HP) in the Western world
as decreased over the last decades, especially in younger birth
ohorts [1]. Also, in the Netherlands the prevalence of HP infec-
ions in young adults decreased from 23% in 1978 to 11% in 1993
1]. The overall prevalence of HP in the Netherlands is estimated at
0–50% [2,3]. In developing nations the prevalence of HP infections
s probably much higher [4]. Despite this decrease in the Western
orld, HP is still one of the most common bacterial pathogens in
umans.
Infection with HP is associated with several clinical complica-
ions, including gastritis, peptic ulcer disease, gastric cancer, and
ucosa-associated lymphoid tissue (MALT) lymphoma. This asso-
iation is clearly described for gastritis and peptic ulcer disease,
n which eradication of HP often cures the condition [5]. Although
or gastric cancer and MALT lymphoma the association was mainly
ased on retrospective epidemiologic research [6], the results of
hese studies had such strength that the working group of the
nternational Agency for Research on Cancer concluded that infec-
ion with HP is a deﬁnite cause of cancer in humans [7]. However,
ereafter this association between HP infection and gastric cancer
as been conﬁrmed in prospective studies such as conducted by
emura et al. [8,9].
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The two most important clinical complications in both num-
bers and costs are peptic ulcer disease and gastric cancer. In 2003
these two conditions togetherwere responsible formore than 2000
deaths and D122 million of direct medical costs in the Netherlands
[10,11]. The exact timelineof thedevelopmentof these serious com-
plications due to a HP infection is unknown yet. Nevertheless, as it
is known that a HP infection is usually acquired in childhood [12],
HP vaccination of infants seems to be the only way of preventing
these clinical complications as a result of a HP infection. However,
no HP vaccine has been marketed yet.
In the development of a HP vaccine a few issues arise. Firstly, HP
infection persists even after a vigorous host immune response. A
future vaccine must therefore generate a response that differs from
a natural response. This can be achieved by generating an even
stronger than natural response or a response through other means.
Secondly, HP antigens may induce hypersensitivity or autoreactive
responses. These two arguments argue against the use of attenu-
ated vaccines or crude whole-cell preparations [13]. Furthermore,
HP strains differ markedly. Vaccines under development must
therefore focus on antigen(s) which are highly conserved and
expressed in vivo. However, the absence of any clear immune
correlates of protection makes the development of a appropriate
vaccine difﬁcult. Urease, cytotoxin-associated gene antigen (CagA),
vacuolating cytotoxin A (VacA) and neutrophil-activating protein
(NAP) have been considered as potential vaccine antigens [14].
Potential vaccines which have been examined in clinical trials most
often contained recombinant urease [14]. However, efﬁcacy (i.e.
immunogenicity) of these vaccines in humans has been disappoint-
ing so far [14]. Recently, Mafertheiner et al. focused on a vaccine
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ontaining the three conserved antigens: CagA, VacA and NAP [15].
hey demonstrated satisfactory safety and immunogenicity of the
accine, which warrants further clinical research.
Nowadays, as in many other countries, in the Netherlands
creening programs are valued with respect to their cost-
ffectiveness (i.e. cost per life year gained) before implementation.
n the Netherlands interventions are certainly considered cost-
ffective if cost-effectiveness is estimated below a threshold of
20,000 per life year gained [16]. This threshold is informal and
ertainly not undisputed, but often used by decision makers. One
mportant factor in cost-effectiveness analyses concerning vaccines
s the discount rate used. Discounting is a technique that reﬂects
xisting time preference: preferring future costs over current costs
nd current beneﬁts and gains over those in the future. For vacci-
ation programs, beneﬁts are usually gained at a later point in time
han the costs are made. For a HP vaccine this is also the case, with
heﬁrst beneﬁts tobe expected at least 20years after vaccination. In
he ﬁrst Dutch guidelines concerning pharmacoeconomic research,
hichwere introduced in 1999, a discount rate of 4% formoney and
ealth outcomes was advocated [17]. In this period it was common
ractice to use the same discount rate for health andmoney [18,19].
uring recent years this insight has been changed and the commit-
ee designingDutch guidelines on pharmacoeconomic research has
ntroduced a discount rate of 1.5% for health, whereas the discount
ate formoney remained at 4% [20,21]. For the background on these
ifferent discount rates we refer to other papers [21,22].
In this paperwecalculate the cost-effectiveness of apotentialHP
accine with respect to preventing peptic ulcer disease and gastric
ancer for the Dutch situation. Furthermore, as indicated above, the
mpact of using different discount rates for health is shown.
. Data and methods
.1. Model
We designed a Markov model to estimate the cost-effectiveness
f a potential HP vaccine [23]. The Markov model was constructed
n TreeAge Data PROtm 2005 and is shown in Fig. 1. The model
onsists of six stages to characterize the progression to (i) gastric
ancer death due to a HP infection, (ii) peptic ulcer death due to
HP infection and (iii) death due to other causes. We analysed
he hypothetical pathway of a cohort of children from birth to 85
ears of age. The situation in which the HP vaccination program
ould be implemented was compared to the current situation of
o vaccination.
able 1
ransition probabilities for each Markov cycle per 5-year period.
arkov cycle Age Peptic ulcer death
Male Female
1 0–4 0.000000 0.000000
2 5–9 0.000000 0.000000
3 10–14 0.000000 0.000000
4 15–19 0.000000 0.000000
5 20–24 0.000010 0.000000
6 25–29 0.000000 0.000000
7 30–34 0.000008 0.000000
8 35–39 0.000007 0.000000
9 40–44 0.000031 0.000008
10 45–49 0.000000 0.000009
11 50–54 0.000035 0.000027
2 55–59 0.000048 0.000049
13 60–64 0.000129 0.000129
14 65–69 0.000288 0.000222
15 70–74 0.000427 0.000286
16 75–79 0.000870 0.000609
17 80–84 0.001194 0.001211tion. Markov cycle speciﬁc transition probabilities are reﬂected by a–c. The dashed
lines and transparent states indicate that all costs related to peptic ulcer disease and
gastric cancer were included although not explicitly modelled.
Transition probabilities “a”–“c” were derived from the number
of gastric cancer deaths, peptic ulcer deaths and all deaths reported
in 2003 for the Netherlands [10]. Data for 2003 were used to be
consistent with other available data (see below). The death rates (r)
were converted into probabilities (p) by solving: p=1− e−rt, where t
is the timeperiod [24]. The5-year transitionprobabilities are shown
in Table 1. We choose a cycle time of 5 years as the number of
gastric cancer and peptic ulcer deaths were only available for the
5-year age classes as given in Table 1. For the situation including HP
vaccination these probabilities were adjusted using the population
attributable risks (PARs) and vaccine efﬁcacy which was assumed
at 80% (range: 50–100%). We evaluated several scenarios with dif-
ferent HP prevalences in the population as the prevalence in the
Netherlands is estimated at 30–50% but shows a decreasing trend
as in most western countries [1]. The exact estimation procedure of
the PARs is described in Appendix A. Ergo, the transition probabili-
ties of death due to gastric cancer and peptic ulcer were decreased
through the PARs and vaccination effectiveness, while the transi-
tion probabilities of death due to other causes were assumed to be
equal in both situations.
For our evaluation the Dutch birth cohort of 2003 was followed
through themodel. This birth cohort consisted of 200,297 children:
102,870 boys and 97,427 girls. We choose a birth cohort as vacci-
Gastric cancer death Other death
Male Female Male Female
0.000000 0.000000 0.006452 0.004827
0.000000 0.000000 0.000923 0.000561
0.000000 0.000000 0.000838 0.000674
0.000000 0.000000 0.002032 0.001155
0.000000 0.000021 0.002691 0.001236
0.000010 0.000020 0.003003 0.001687
0.000008 0.000023 0.003583 0.001994
0.000030 0.000031 0.004822 0.003676
0.000116 0.000103 0.008563 0.006343
0.000229 0.000078 0.013570 0.011224
0.000342 0.000217 0.022124 0.016773
0.000808 0.000273 0.037070 0.024192
0.001191 0.000465 0.059604 0.035385
0.001983 0.000711 0.100339 0.056321
0.003493 0.001239 0.169303 0.094210
0.004345 0.001973 0.276526 0.163343
0.006964 0.002741 0.440646 0.288807
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Table 2
Gender- and age-speciﬁc population costs due to peptic ulcer disease and gastric
cancer in the Netherlands in 2003 (million D ).
Age Peptic ulcer Gastric cancer
Male Female Male Female
0–4 0 0.1 0 0
5–9 0 0 0 0
10–14 0.2 0 0 0
15–19 0.1 0 0 0
20–24 0.3 0.1 0 0
25–29 0.4 0.2 0 0
30–34 0.8 0.3 0.1 0.2
35–39 1 0.5 0.4 0.3
40–44 1.7 0.7 0.6 0.5
45–49 1.4 0.9 0.9 0.8
50–54 2.2 1.3 1.8 1.1
55–59 2.6 1.5 3.2 1.6
60–64 2.6 1.3 4 1.9











































Parameter values with the accompanying distributions used in the Markov model.
Input variable Base case Distribution Reference
Birth cohort
Male 102,870 – [5]
Female 97,427 – [5]
Vaccine inputs
Efﬁcacy % (range) 80 (50–100) Triangular [21]
Doses per course 3 – [21]
Cost per dose D 50 – [21]
Helicobacter pylori risksa
PAR peptic ulcer range 0.19–0.54 Implicitly deﬁned [24,25]
PAR gastric cancer range 0.13–0.43 Implicitly deﬁned [24,25]0–74 4.6 4.9 5.7 2.8
5–79 4.2 7.6 4.9 3.2
0–84 3.6 7.5 3.4 2.8
ation for HP is assumed to be best done in infants. For simplicity,
t was assumed that all children were vaccinated (100% coverage).
his may be justiﬁed by the fact that the vaccination coverage in
he Netherlands is high, for the national vaccination program this
s approximately 96% [23]. The immunization is assumed to consist
f three doses given in the ﬁrst year of life. So, we assumed that
ll children were vaccinated after 1 year. Furthermore, we assumed
hat vaccination in children provided a lifelong protection for HP-
ssociated illness, because both the infection rate in adults is low
nd a vaccine may give a lifetime protection.
.2. Costs
Both the costs of vaccination and the directmedical costs associ-
ted with gastric cancer and peptic ulcer disease were considered.
ll costs were reported in D2003. The costs of the vaccine were
ssumed at D50 per dose [26]. These costs were not discounted as
heyweremadeon t=0.Directmedical costs associatedwithgastric
ancer and peptic ulcer disease were available for 2003 [27]. In par-
icular, the total costs for the whole Dutch population due to peptic
lcer disease and gastric cancer were determined at D70.7 million
nd D51.7million, respectively [27]. Subsequently these yearly total
osts were stratiﬁed to gender and 5-year age classes (Table 2).
hese gender and age-group speciﬁc costs were then divided by
he total number of gender and age-group speciﬁc deaths due to
astric cancer and peptic ulcer disease, respectively. Subsequently
hese gender and age-group speciﬁc ‘costs per peptic ulcer death’
nd ‘costs per gastric cancer death’ were attached to the accom-
anying states of the Markov model. Note that both cost estimates
nclude the costs associated with peptic ulcer disease and gastric
ancer, respectively, for non-deceasedpersons aswell. For example,
f 1 out of 100 persons diagnosed with peptic ulcer dies the ‘costs
er peptic ulcer death’ represents the costs of all these 100 persons,
ncluding the 99 patients not being deceased. Accordingly, the eco-
omic consequences as a result of HP vaccination are fully taken
nto account, yet be it crudely in being assigned to deaths only.
.3. Life years gained (LYG)In the model the number of life years lived by the 2003 birth
ohort was estimated both for the scenarios with and without HP
accination. As mentioned, in the ﬁrst case the transition probabil-
ties of death due to gastric cancer and peptic ulcer were decreased
hrough the PARs and vaccination effectiveness. The transitionPAR, population attributable risk.
a Several Helicobacter pylori prevalence scenarios (10%, 20%, 30%, 40% and 50%)
were evaluated. See Appendix A for details.
probabilities of death due to other causeswere assumed to be equal
in both cases. The difference in total number of live years lived
between these scenarios was considered to be the total number
of LYG by HP vaccination. To study the impact of different discount
rates for health outcomes the life years were discounted using the
current discount rate of 1.5% as well as the former used discount
rate of 4% [16,19,20].
2.4. Cost-effectiveness analysis
The incremental cost-effectiveness of HP vaccination compared
to the current situation without HP vaccination was estimated in
terms of costs per LYG. To evaluate the level of uncertainty in the
outcomes a probabilistic sensitivity analysis was undertaken with
probability distributions for vaccine efﬁcacy and the PARs [28].
The model input parameter values together with the associated
distributions are given in Table 3. As no information on vaccine
effectiveness was available, we used the estimates given by the
manufacturersaspreviously reportedbyRupnowetal. [26].Vaccine
effectiveness was assumed to follow a triangular distribution.
Thedistribution for the PARs is implicitly deﬁned as for thenatu-
ral logarithmof theRR (LnRR),whichwasused to construct thePARs
(see Appendix A), the normal distributionmay be assumed to apply
[29,30]. As mentioned above to evaluate the level of uncertainty
associated with the HP prevalence we analysed several prevalence
scenarios (10%, 20%, 30%, 40% and 50%). For each scenario we con-
ducted 10,000 Monte Carlo simulations [28]. These results were
subsequently presented in cost-effectiveness acceptability curves
[31,32]. In the Netherlands, for cost-effectiveness decision makers
use an informal threshold of D20,000/LYG (i.e. prevention programs
are certainly considered cost-effective when cost-effectiveness is
estimated below D20,000/LYG) [33].
As we are still a long way from the registration of an effective HP
vaccine that canhave prophylactic use in humans, the exact efﬁcacy
that such a vaccine will have is still very uncertain [14]. Therefore,
to fully evaluate the impact of the vaccine efﬁcacy on the outcomes
an univariate sensitivity analysis was performed on this parameter
[28]. In this univariate sensitivity analysis we estimated the cost-
effectiveness for a vaccine efﬁcacy of 50% as well as 100% for all HP
prevalence scenarios.
3. Results
Table 4 presents the results of the expected value analysis for
both discount rates for health. The estimated total vaccination costs
incurred by the hypothetical cohort are shown together with the
averted costs and LYG when compared to the current situation
without HP vaccination. It is shown that the incremental cost-
effectiveness ratio decreases when the HP prevalence increases.
R. de Vries et al. / Vaccine 27 (2009) 846–852 849
Table 4









































et al. conducted a cost-effectiveness analysis on HP vaccination for
the US [26]. They estimated that, if future health beneﬁts and costs
are discounted at 3% as recommended for theUS, aHPvaccine could
be cost-saving. As in this paper, they included the disease burdens
from peptic ulcer and gastric cancer only [26].haded cells reﬂect scenarios where cost-effectiveness is estimated below the infor
YG, life years gained.
CER, incremental cost-effectiveness ratio.
hen applying the current discount rate of 1.5% for health, the
ost-effectiveness of HP vaccination is estimated below the infor-
al Dutch threshold of D20,000/LYG when the HP prevalence is
ssumed ≥20% in the Dutch population. However, when applying
he former 4% discount rate even with a HP prevalence of 50% HP
accination is still estimated potentially not cost-effective (incre-
ental cost-effectiveness: D57,000/LYG).
The results of the Monte Carlo simulations for the different HP
revalence scenarios are given in Table 5. The median together
ith the 95th percentiles are presented for both discount rates. The
robability that HP vaccination is cost-effective (<D20,000/LYG) is
stimated below 0.5 for all ﬁve HP prevalence scenarios when a
iscount rate of 4% is applied. However, when using the current
iscount rate of 1.5% HP vaccination is estimated cost-effective
ith a probability of more than 0.95 when the HP prevalence is
ssumed ≥30% in the Dutch population. The accompanying cost-
ffectiveness acceptability curves for a discount rate of 1.5% and 4%
or health are depicted in Figs. 2 and 3, respectively.
The inﬂuence of the vaccine efﬁcacy on the cost-effectiveness
s shown in Fig. 4. When vaccine efﬁcacy is increased to 100% the
ncremental cost-effectiveness ratio is decreased by approximately
5% for both health discount rates and all HP prevalence scenarios.
ote that here a decrease in incremental cost-effectiveness is in
avour of HP vaccination. The incremental cost-effectiveness ratio
s on the other hand increased by approximately 58% compared
o the baseline analysis (i.e. vaccine efﬁcacy=80%) when vaccine
fﬁcacy is assumed at 50%. Furthermore, the effect of a change in
fﬁcacy is only slightly increased if HP prevalence is increased.
. Discussion
In this study, we estimated the cost-effectiveness of a potential
P vaccine. Although we are still far from developing a HP vaccine
hat can have prophylactic uses in humans, we evaluated the pos-
ible economic consequences of HP vaccination [15]. Here, we only
ook the preventive effect on peptic ulcer and gastric cancer into
ccount. Furthermore, we assessed the inﬂuence of the discount
ate for health on the results. We speciﬁcally compared the out-
omes using a 4% discount rate with using a 1.5% discount rate as
ecently this discount rate has been changed from 4% to 1.5% in the
utch guidelines for pharmacoeconomic research [17,20].utch threshold of D 20,000/LYG.
According to the current Dutch guidelines and informal cost-
effectiveness threshold (D20,000/LYG) this study reveals that a HP
vaccine has the potential to be cost-effective for theDutch situation
when the HP prevalence is 20% or more. When the HP prevalence
equals or exceeds 30% the probability of being cost-effective is esti-
mated to be even >0.95.
As the development of a HP vaccine is still in progress only a few
cost-effectiveness studies have been published so far [26]. RupnowFig. 2. Cost-effectiveness acceptability curves for the ﬁve different Helicobacter
pylori prevalence scenarios using a 1.5% discount rate health; probability of being
cost-effective for a given cost-effectiveness threshold. The red vertical line rep-
resents the informal Dutch threshold of D 20,000/LYG. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version
of the article.)
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Table 5
Results of the probabilistic sensitivity analysis based on 10,000 Monte Carlo simulations.
Shaded cells reﬂect scenarios where cost-effectiveness is estimated below the informal D
aDiscount rate for health.
Fig. 3. Cost-effectiveness acceptability curves for the ﬁve different Helicobacter
pylori prevalence scenarios using a 4% discount rate for health; probability of being
cost-effective for a given cost-effectiveness threshold. The red vertical line rep-
resents the informal Dutch threshold of D 20,000/LYG. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version
of the article.)
Fig. 4. Univariate sensitivity analyses on vaccine efﬁcacy for the ﬁve different Helicobacte
vertical red line at x=0 indicates the expected cost-effectiveness for the different scenario
ratio. (For interpretation of the references to color in this ﬁgure legend, the reader is referutch threshold of D 20,000/LYG LYG, life years gained.
There are several limitations of our study. Pharmacoeconomic
analyses, in general, prefer the cost per quality adjusted life year
(QALY) as the main outcome measure. However, as there were no
data available on the decrease in quality of life due to peptic ulcer
disease or gastric cancer it was not possible to provide reliable esti-
mates of QALYs. In economic evaluations the costs per QALY are
in general more favourable in terms of cost-effectiveness than the
costs per LYG.
As there were no Dutch data available on the incidence of both
peptic ulcer disease and gastric cancer, we calculated the ‘costs
per peptic ulcer death’ and the ‘costs per gastric cancer death’ by
dividing the total costs by the number of deaths. This probably
resulted in a conservative estimation of the cost-effectiveness as
there were costs associated with age-categories where no deaths
were reported (e.g. males aged 10–14 years suffering from peptic
ulcer disease). These costs, which could potentially also be averted
by vaccination, were not included in the analysis. Also, the prag-
matic choice of assigning costs to deathsmay involve an actual shift
of some those costs years into the future. Given the procedure of
discounting this consequently involves a potential underestimation
of those costs and again renders a conservative estimate of cost-
effectiveness. Furthermore, we did not take any costs related to the
set-up of an universal HP vaccination program into account. Con-
sequently, the outcomes are not inﬂuenced by the coverage as all
the direct medical costs currently considered in this analysis are
directly related to the number of people being vaccinated.
r pylori (HP) prevalence scenarios using a 4% and 1.5% discount rate for health. The
s, where vaccine efﬁcacy was assumed at 80%. ICER= incremental cost-effectiveness
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Furthermore, the possible effects of HP vaccination on gastritis
nd the relative rare disease MALT lymphoma were not modelled
n this analysis. Whereas the causal relationship between HP and
astritis is clearly conﬁrmed [5], there are strong believes that this
elationship also exists for MALT lymphoma [6]. So, inclusion of
oth disease states in the Markov model is likely to lead to a more
avourable cost-effectiveness of HP vaccination as both diseases,
nd associated costs and decreases in quality of life, could possibly
lso be prevented by vaccination. Furthermore, as no HP vaccine is
urrently available there are still a lot of uncertainties associated
ith the parameter values used in the model. For example, only
rude estimates for vaccine effectiveness can be used. However, we
ook these uncertainties into account in both a probabilistic and
eterministic sensitivity analysis. Finally, the exact HP prevalence
n the Netherlands is unknown [1–3]. However, it is known that
he prevalence has been declining in western countries the last
ecades [1]. In general, the cost-effectiveness of vaccination pro-
rams largely depends on the incidence of the particular infectious
isease in the population. To take this uncertainty related to the
P prevalence and the trend in decrease into account we evaluated
everal scenarios with a prevalence ranged from 0.1 to 0.5.
As it is likely that the HP incidence will decline further in the
ext decades, a preventive program aimed at high-risk groups
i.e. high-prevalence groups) may become more feasible than a
opulation-based approach. Previously it has been shown that
he prevalence in the migrant population in the Netherlands is
onsiderably higher than in the autochthonous population [2,34].
ccordingly, children of immigrants from high-endemic countries
ay constitute a target group for HP vaccination. With respect to
epatitis B a speciﬁc vaccination program for children of parents
romhigh-HepatitisBprevalencecountries recentlyhasbeenadded
o the Dutch national immunization program [35]. Key factors for
he success of such a targeted vaccination program would certainly
e the coverage rate achieved among these autochthonous pop-
lations, the possibility to achieve a relatively low price for the
accination despite the non-universal setting and an enhancement
f general notion that preventive programs are worthwhile invest-
ents.
It is clear that preventive programs beneﬁt from a lowering in
iscount rate [36–39]. In general vaccination and screening pro-
rams most often avert diseases which would have occurred in the
far) future. Ergo, while the monetary investments need to be made
ow the beneﬁts are only gained later in time. In this study these
eneﬁcial effects of a change in discount rate are clearly shown.
hen using the former 4% discount rate, the cost-effectiveness
atios of the different HP prevalence scenarios are consistently
uch higher compared to the cost-effectiveness ratios when using
he new 1.5% discount rate for health. In case of a HP vaccine this
elevant beneﬁcial effect of a lower discount rate for health was
xpected as most of the health beneﬁts are gained after a long
eriodof time. Ingeneral, preventionprogramsmightbecomemore
ncreasingly introduced due to the implementation of a lower dis-
ount rate for health. In this example, assuming a HP prevalence
f 30%, according to the current Dutch guidelines HP vaccination
s considered cost-effective (p>0.95) and should be implemented
rom a pharmacoeconomic point of view. However, when the for-
er discount rate of 4% is applied HP vaccination is estimated
ot cost-effective (ICER> D80,000/LYG) and should not be imple-
ented.
As indicated above, the literature is accumulating that health
hould indeed be discounted at a signiﬁcantly lower discount rate
han money [36,39]. Factors contributing to lower time preference
or health than formoney are the desire to eliminate dread [40], the
ncreasing value of health over time [36] and the potential double
iscounting of health effects [41]. Even zero and negative time pref-
rences have been suggested for health. In particular, Van der Pol27 (2009) 846–852 851
and Cairns reviewed the literature on empirical assessments of the
discount rate, showing that up to 39% of respondents in individual
studies expressed negative discount rates and up to 36% expressing
no timepreference (discount rate of 0%) [40]. In their own empirical
study both authors found approximately 20% of persons exhibiting
zero or negative time preference [40]. Previously, Loewenstein and
Prelec analysed preferences for various sequences of events, also
indicating a possible negative rate of time preference [42]. Ergo,
consensus seems to come on using lower discount rates for health
than for money, down to potentially zero or even negative rates for
health. For achieving an adequate valuation of preventive interven-
tions such as vaccination, the issue of zero or negative discounting
certainly warrants more research in the near future.
In conclusion, in this paperwe showed thatHPvaccination could
possibly be a cost-effective intervention. However, among other
things this depends to a large extend on the prevalence of HP in
the population. Although we performed a probabilistic sensitivity
analysis on vaccine efﬁcacy and PARs, one should be reserved in
drawing conclusions from this study as no HP vaccine has been
registered to this moment. Therefore, future research is required to
further evaluate the cost-effectiveness of HP vaccination. Further-
more, as there are alternative strategies to decrease the number
of complications caused by HP infections (e.g. population-based
screening for HP and subsequent treatment [43]), HP vaccination
should be compared to those in future economic analyses as well.
Finally, we showed the large impact of the discount rate for health
on the cost-effectiveness of a HP vaccination program, illustrative
for other vaccination programs in the Netherlands.
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Appendix A
The estimation of the population attributable risks (PARs) of a
HP infection for both gastric cancer and peptic ulcer disease for
the Netherlands is crucial in our analysis. The PAR estimates the
proportion of disease (i.e. gastric cancer or peptic ulcer disease)
in the study population that is attributable to the exposure (here
HP) [30]. The PAR depends on the prevalence of HP infection in the
Netherlands, PHP, and the strength of its association (relative risk)
with the disease:
PAR = PHP(RR − 1)
1 + PHP(RR − 1)
with the relative risk (RR) being the ratio of the probability of the
disease occurring in the exposed group versus the non-exposed
group [30]. TheRRswereextracted fromtwometa-analyses [44,45].
In particular, the RRs for peptic ulcer disease and gastric cancer
were estimated at 3.3 (95% C.I.: 2.6–4.4) and 2.5 (95% C.I.: 1.9–3.4),
respectively.
Data from adults show a prevalence of HP infection of 30–50%
in the Netherlands [2,3]. As yet the prevalence has decreased in
most Western countries we calculated the PARs for several scenar-
ios with HP prevalences ranging from 10% to 50% [1]. The estimated
Dutch PARs associated with gastric cancer and peptic ulcer disease
are shown in Table 6. Accordingly, the proportions of peptic ulcer
disease and gastric cancer attributable to a HP infection were esti-
mated at 0.19–0.54 and 0.13–0.43, respectively, depending on the
HP prevalence.
852 R. de Vries et al. / Vaccine
Table 6
Population attributable risks (PARs) of a Helicobacter pylori (HP) infection for peptic
ulcer disease and gastric cancer.
HP prevalence PAR peptic ulcer (95% C.I.) PAR gastric cancer (95% C.I.)
0.1 0.19 (0.14–0.25) 0.13 (0.08–0.19)
0.2 0.32 (0.24–0.41) 0.23 (0.15–0.32)





































2005;27:1647–57..4 0.48 (0.39–0.58) 0.38 (0.27–0.49)
.5 0.54 (0.44–0.63) 0.43 (0.31–0.55)
.I., conﬁdence interval.
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